Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Cell
2011 Nov 23;1475:1011-23. doi: 10.1016/j.cell.2011.09.055.
Show Gene links
Show Anatomy links
Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs.
Fribourg M
,
Moreno JL
,
Holloway T
,
Provasi D
,
Baki L
,
Mahajan R
,
Park G
,
Adney SK
,
Hatcher C
,
Eltit JM
,
Ruta JD
,
Albizu L
,
Li Z
,
Umali A
,
Shim J
,
Fabiato A
,
MacKerell AD
,
Brezina V
,
Sealfon SC
,
Filizola M
,
González-Maeso J
,
Logothetis DE
.
???displayArticle.abstract???
Atypical antipsychotic drugs, such as clozapine and risperidone, have a high affinity for the serotonin 5-HT(2A) G protein-coupled receptor (GPCR), the 2AR, which signals via a G(q) heterotrimeric G protein. The closely related non-antipsychotic drugs, such as ritanserin and methysergide, also block 2AR function, but they lack comparable neuropsychological effects. Why some but not all 2AR inhibitors exhibit antipsychotic properties remains unresolved. We now show that a heteromeric complex between the 2AR and the G(i)-linked GPCR, metabotropic glutamate 2 receptor (mGluR2), integrates ligand input, modulating signaling output and behavioral changes. Serotonergic and glutamatergic drugs bind the mGluR2/2AR heterocomplex, which then balances Gi- and Gq-dependent signaling. We find that the mGluR2/2AR-mediated changes in Gi and Gq activity predict the psychoactive behavioral effects of a variety of pharmocological compounds. These observations provide mechanistic insight into antipsychotic action that may advance therapeutic strategies for disorders including schizophrenia and dementia.
Aloyo,
Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors.
2009, Pubmed
Aloyo,
Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors.
2009,
Pubmed
Barducci,
Well-tempered metadynamics: a smoothly converging and tunable free-energy method.
2008,
Pubmed
Barela,
An epilepsy mutation in the sodium channel SCN1A that decreases channel excitability.
2006,
Pubmed
,
Xenbase
Bespalov,
Habituation deficits induced by metabotropic glutamate receptors 2/3 receptor blockade in mice: reversal by antipsychotic drugs.
2007,
Pubmed
Branduardi,
From A to B in free energy space.
2007,
Pubmed
Carriba,
Detection of heteromerization of more than two proteins by sequential BRET-FRET.
2008,
Pubmed
Du,
Characteristic interactions with phosphatidylinositol 4,5-bisphosphate determine regulation of kir channels by diverse modulators.
2004,
Pubmed
,
Xenbase
Egan,
Creation of a constitutively activated state of the 5-hydroxytryptamine2A receptor by site-directed mutagenesis: inverse agonist activity of antipsychotic drugs.
1998,
Pubmed
Ernst,
Monomeric G protein-coupled receptor rhodopsin in solution activates its G protein transducin at the diffusion limit.
2007,
Pubmed
González-Maeso,
Identification of a serotonin/glutamate receptor complex implicated in psychosis.
2008,
Pubmed
González-Maeso,
Psychedelics and schizophrenia.
2009,
Pubmed
González-Maeso,
Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior.
2007,
Pubmed
González-Maeso,
Quantitative stoichiometry of G-proteins activated by mu-opioid receptors in postmortem human brain.
2002,
Pubmed
Gründer,
The 'atypicality' of antipsychotics: a concept re-examined and re-defined.
2009,
Pubmed
Han,
Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation.
2009,
Pubmed
He,
Identification of a potassium channel site that interacts with G protein betagamma subunits to mediate agonist-induced signaling.
1999,
Pubmed
He,
Identification of critical residues controlling G protein-gated inwardly rectifying K(+) channel activity through interactions with the beta gamma subunits of G proteins.
2002,
Pubmed
Kinon,
A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia.
2011,
Pubmed
Kondo,
Anti-/Propsychotic drug signaling via heteromeric GPCRs--a balancing act?
2011,
Pubmed
Lazaridis,
Effective energy function for proteins in lipid membranes.
2003,
Pubmed
Lieberman,
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
2005,
Pubmed
Logothetis,
The beta gamma subunits of GTP-binding proteins activate the muscarinic K+ channel in heart.
,
Pubmed
Lopes,
Alterations in conserved Kir channel-PIP2 interactions underlie channelopathies.
2002,
Pubmed
,
Xenbase
Lopez-Gimenez,
The alpha1b-adrenoceptor exists as a higher-order oligomer: effective oligomerization is required for receptor maturation, surface delivery, and function.
2007,
Pubmed
Meltzer,
In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.
2008,
Pubmed
Meltzer,
Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values.
1989,
Pubmed
Milligan,
G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function.
2009,
Pubmed
Moreno,
Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists.
2011,
Pubmed
Moreno,
Group II metabotropic glutamate receptors and schizophrenia.
2009,
Pubmed
Morris,
PCP: from pharmacology to modelling schizophrenia.
2005,
Pubmed
Mouri,
Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment.
2007,
Pubmed
Patil,
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
2007,
Pubmed
Pichon,
Disrupting 5-HT(2A) receptor/PDZ protein interactions reduces hyperalgesia and enhances SSRI efficacy in neuropathic pain.
2010,
Pubmed
Provasi,
Ligand-induced modulation of the free-energy landscape of G protein-coupled receptors explored by adaptive biasing techniques.
2011,
Pubmed
Reimherr,
The use of MK-801, a novel sympathomimetic, in adults with attention deficit disorder, residual type.
1986,
Pubmed
Rives,
Crosstalk between GABAB and mGlu1a receptors reveals new insight into GPCR signal integration.
2009,
Pubmed
Rosenbaum,
The structure and function of G-protein-coupled receptors.
2009,
Pubmed
Ross,
Neurobiology of schizophrenia.
2006,
Pubmed
Urizar,
CODA-RET reveals functional selectivity as a result of GPCR heteromerization.
2011,
Pubmed
Uslaner,
Combined administration of an mGlu2/3 receptor agonist and a 5-HT 2A receptor antagonist markedly attenuate the psychomotor-activating and neurochemical effects of psychostimulants.
2009,
Pubmed
Vanommeslaeghe,
CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields.
2010,
Pubmed
Vilardaga,
Conformational cross-talk between alpha2A-adrenergic and mu-opioid receptors controls cell signaling.
2008,
Pubmed
Weiner,
5-hydroxytryptamine2A receptor inverse agonists as antipsychotics.
2001,
Pubmed
Whorton,
A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein.
2007,
Pubmed
Woolley,
The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity.
2008,
Pubmed
Yokoi,
Impairment of hippocampal mossy fiber LTD in mice lacking mGluR2.
1996,
Pubmed
